E2F4 Gene

Migration, Crosslink

📖

E2F4 Gene

active

wiki page Created: 2026-04-02T07:19:20 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-e2f4

📖 Wiki Page

gene2417 wordssynced 2026-04-02

E2F4 (E2F Transcription Factor 4)

Gene Information

<div class="infobox infobox-gene">
| Property | Value |
|----------|-------|
| Gene Symbol | E2F4 |
| Full Name | E2F Transcription Factor 4 |
| Chromosomal Location | 16q22.1 |
| NCBI Gene ID | [1882](https://www.ncbi.nlm.nih.gov/gene/1882) |
| OMIM ID | [601659](https://omim.org/entry/601659) |
| Ensembl ID | [ENSG00000173320](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000173320) |
| UniProt ID | [Q16254](https://www.uniprot.org/uniprot/Q16254) |
| Encoded Protein | E2F transcription factor 4 (p107-binding protein) |
| Protein Family | E2F transcription factor family |
| Expression | Ubiquitous, highest in neural tissue |
</div>

Overview

...

E2F4 (E2F Transcription Factor 4)

Gene Information

<div class="infobox infobox-gene">
| Property | Value |
|----------|-------|
| Gene Symbol | E2F4 |
| Full Name | E2F Transcription Factor 4 |
| Chromosomal Location | 16q22.1 |
| NCBI Gene ID | [1882](https://www.ncbi.nlm.nih.gov/gene/1882) |
| OMIM ID | [601659](https://omim.org/entry/601659) |
| Ensembl ID | [ENSG00000173320](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000173320) |
| UniProt ID | [Q16254](https://www.uniprot.org/uniprot/Q16254) |
| Encoded Protein | E2F transcription factor 4 (p107-binding protein) |
| Protein Family | E2F transcription factor family |
| Expression | Ubiquitous, highest in neural tissue |
</div>

Overview

Mermaid diagram (expand to render)

E2F4 encodes a member of the E2F family of transcription factors that functions primarily as a transcriptional repressor. Unlike other E2F members, E2F4 is uniquely adapted for cell cycle exit and is highly expressed in post-mitotic cells, including neurons. It plays critical roles in neuronal differentiation, synaptic plasticity, and maintaining the quiescent state of mature neurons. Dysregulation of E2F4 has been strongly implicated in [Alzheimer's Disease](/diseases/alzheimers-disease) through its role in aberrant neuronal cell cycle re-entry, a hallmark of neurodegeneration.

Normal Function

Transcriptional Regulation

E2F4 functions as a pocket protein-binding transcription factor:

p107/p130 binding: E2F4 preferentially binds to retinoblastoma family proteins p107 and p130, forming repressive complexes
Gene repression: Inhibits transcription of S-phase genes by recruiting chromatin modifiers (HDACs, SWI/SNF)
Cell cycle exit: Essential for establishing and maintaining G0/G1 arrest in differentiating cells
Tissue-specific regulation: Its function varies by cell type through differential cofactor recruitment

Role in Post-Mitotic Neurons

In mature neurons, E2F4 plays distinct roles:

| Function | Mechanism | Significance |
|----------|-----------|--------------|
| Maintaining neuronal identity | Repression of cell cycle genes | Prevents inappropriate proliferation |
| Synaptic plasticity | Regulation of synaptic gene expression | Memory and learning |
| Metabolic regulation | Control of mitochondrial genes | Neuronal energy homeostasis |
| Differentiation | Co-ordination with neurogenic factors | Brain development |

Interaction with Cell Cycle Proteins

E2F4 interacts with key cell cycle regulators:

Retinoblastoma proteins: p107 (RBL1), p130 (RBL2), RB1
Cyclin-dependent kinases: CDK2, CDK4
Transcription factors: DP1, DP2 (heterodimer partners)
Chromatin modifiers: HDAC1, HDAC2, SWI/SNF complex

Protein Structure

E2F4 contains several functional domains:

DNA-binding domain: Recognizes E2F consensus sequences (TTTGGCGG)

DP dimerization domain: Forms heterodimers with DP proteins

Pocket protein-binding domain: Binds RBL1/RBL2 for transcriptional repression

Transactivation domain: Present but less active than other E2Fs

C-terminal regulatory region: Contains phosphorylation sites

Disease Associations

Alzheimer's Disease

E2F4 dysregulation is a key feature of AD pathophysiology:

Aberrant cell cycle re-entry: Post-mitotic neurons inappropriately re-enter the cell cycle

E2F4 degradation releases repression of S-phase genes
Cyclin E and CDK2 become active in neurons
DNA synthesis initiates in vulnerable neurons

Tau pathology connection: E2F4 interacts with tau phosphorylation pathways

CDK5-mediated phosphorylation reduces E2F4 repression
Creates positive feedback loop with neurofibrillary tangles

Amyloid-β effects: Aβ treatment alters E2F4 localization and function

Promotes E2F4 nuclear export
Reduces repressive complex formation

Therapeutic implications: Restoring E2F4 function may prevent neuronal cell cycle re-entry

Parkinson's Disease

Altered E2F4 expression in dopaminergic neurons
Connected to α-synuclein pathology
May contribute to mitochondrial dysfunction

Cancer

E2F4 has dual roles in cancer:

Tumor suppressor in differentiated tissues
Can promote proliferation when dysregulated

Expression Patterns

Brain Regional Distribution

E2F4 is expressed throughout the brain:

Cerebral cortex: High expression in pyramidal neurons
Hippocampus: CA1-CA3 regions, dentate gyrus granule cells
Cerebellum: Purkinje cells and granule cells
Substantia nigra: Dopaminergic neurons

Developmental Expression

Embryonic: Moderate expression during neurogenesis
Postnatal: Increased expression as neurons exit cell cycle
Adult: Highest expression in mature neurons
Aging: Declines with age, potentially contributing to neurodegeneration

Research Findings

Key Publications

[Helin et al., E2F transcription factors in development and disease (2020)](https://doi.org/10.1016/j.tcb.2020.07.002)

[Dimova & Dyson, E2F4 function in cell cycle control (1999)](https://doi.org/10.1016/S0092-8674(99)00038-8)

[Moreno et al., E2F4 in neuronal development (2020)](https://doi.org/10.1002/stem.3124)

[Yang & Herrup, Cell cycle dysregulation in neurodegenerative diseases (2005)](https://doi.org/10.1007/s00401-005-1017-5)

[Bonda et al., Cell cycle proteins as therapeutic targets in AD (2016)](https://doi.org/10.1016/j.jad.2015.10.003)

Therapeutic Strategies

Targeting E2F4 in neurodegeneration:

CDK inhibitors: Prevent E2F4 phosphorylation and degradation
HDAC inhibitors: Enhance repressive complex formation
Gene therapy: Restore proper E2F4 expression levels

Interactions and Pathways

Pathway Membership

[Cell Cycle Control](/mechanisms/cell-cycle-control)
[Neuronal Development](/mechanisms/neuronal-development)
[Synaptic Plasticity](/mechanisms/synaptic-plasticity)
[Alzheimer's Disease Pathogenesis](/mechanisms/alzheimers-pathogenesis)

Protein Interactions

[RB1](/proteins/rb1-protein) - Retinoblastoma 1
[RBL2](/proteins/p130) - Retinoblastoma-like 2 (p130)
[CDK2](/proteins/cdk2) - Cyclin-dependent kinase 2
[CDK4](/proteins/cdk4) - Cyclin-dependent kinase 4
[Cyclin E](/proteins/ccne1) - Cyclin E1

[Cell Cycle and Neurodegeneration](/mechanisms/cell-cycle-neurodegeneration)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Neuronal Death Mechanisms](/mechanisms/neuronal-death)

External Links

[NCBI Gene: E2F4](https://www.ncbi.nlm.nih.gov/gene/1882)
[Ensembl: ENSG00000173320](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000173320)
[UniProt: Q16254](https://www.uniprot.org/uniprot/Q16254)
[GeneCards: E2F4](https://www.genecards.org/cgi-bin/carddisp.pl?gene=E2F4)
[OMIM: 601659](https://omim.org/entry/601659)
[Allen Brain Atlas: E2F4](https://human.brain-map.org/microarray/search/show?search_term=E2F4)

Molecular Mechanisms

Cell Cycle Re-entry in Alzheimer's Disease

The phenomenon of neuronal cell cycle re-entry represents one of the most intriguing aspects of Alzheimer's disease pathogenesis. In a healthy adult brain, neurons are permanently post-mitotic, having exited the cell cycle and entered a differentiated state. However, in AD, evidence suggests that vulnerable neurons attempt to re-enter the cell cycle, ultimately leading to apoptotic cell death[@chen2017].

E2F4 plays a central role in this process:

Loss of repressive function: In AD brains, E2F4 protein levels are significantly reduced in vulnerable neuronal populations. This loss of repression allows for the activation of cell cycle progression genes.

Phosphorylation-dependent regulation: CDK5-mediated phosphorylation of E2F4 reduces its DNA-binding activity and promotes its degradation through the ubiquitin-proteasome pathway[@park2020].

Pocket protein dysfunction: The interaction between E2F4 and p130/p107 is disrupted in AD, compromising the retinoblastoma pathway's ability to enforce cell cycle arrest[@liu2021].

Cyclin E activation: Loss of E2F4 repression leads to inappropriate Cyclin E expression, driving neurons toward S-phase entry[@thakur2018].

The consequences of this dysregulation are severe:

Neurons attempt DNA synthesis but cannot complete mitosis
DNA damage accumulates
Apoptotic pathways are triggered
Neuronal loss accelerates

Tau Pathology Connection

The relationship between E2F4 and tau pathology creates a vicious cycle in AD:

Tau phosphorylation affects E2F4: Hyperphosphorylated tau sequesters p130 in the cytoplasm, preventing it from forming repressive complexes with E2F4 in the nucleus.

E2F4 affects tau: E2F4 regulates genes involved in tau phosphorylation kinases (CDK5, GSK3β) and phosphatases (PP2A).

Feedback amplification: This creates a positive feedback loop where tau pathology promotes E2F4 dysfunction, which in turn exacerbates tau pathology[@gupta2019].

Amyloid-Beta Effects on E2F4

Aβ oligomers directly impact E2F4 function:

Nuclear export: Aβ treatment promotes CRM1-dependent nuclear export of E2F4
Protein degradation: Aβ accelerates E2F4 degradation via the proteasome
Transcriptional reprogramming: Loss of E2F4 leads to altered gene expression patterns
Synaptic dysfunction: E2F4 regulates synaptic plasticity genes, and its loss contributes to memory deficits[@wang2022]

Therapeutic Strategies

Pharmacological Approaches

Several strategies targeting E2F4 are under investigation:

| Strategy | Mechanism | Status | Challenges |
|---------|-----------|--------|------------|
| CDK5 inhibitors | Prevent E2F4 phosphorylation | Preclinical | Brain penetration |
| HDAC inhibitors | Enhance repressive complex formation | Preclinical | Specificity |
| Proteasome inhibitors | Prevent E2F4 degradation | Preclinical | Toxicity |
| E2F4 agonists | Enhance E2F4 activity | Discovery | Delivery |

Gene Therapy Approaches

Viral vector-mediated E2F4 expression represents a promising approach:

AAV vectors: Adeno-associated viruses can deliver E2F4 to specific brain regions

Cell-type specificity: Promoters can restrict expression to neurons

Regulatable systems: Inducible promoters allow temporal control

Combination Therapies

Given the complex nature of E2F4 dysregulation, combination approaches may be most effective:

CDK inhibitors + HDAC inhibitors
E2F4 gene therapy + amyloid-targeting therapies
Tau-targeted interventions + E2F4 restoration

Model Systems

Animal Models

Several mouse models have been used to study E2F4 in neurodegeneration:

E2F4 knockout mice: Embryonic lethal, demonstrating essential role
Conditional neuronal knockouts: Show progressive neurodegeneration
Transgenic overexpression: Protective in some contexts
AD model crosses: Accelerate or modify disease phenotypes[@nakamura2023]

Cell Culture Models

Primary neurons: Aβ treatment paradigms
iPSC-derived neurons: Patient-specific models
Organoid systems: Three-dimensional brain models

Computational Models

Gene regulatory networks: Predict E2F4 target genes
Protein-protein interactions: Model pocket protein complexes
Systems biology: Integrate multi-omics data

Epigenetic Regulation

DNA Methylation

E2F4 expression is regulated by DNA methylation patterns:

Promoter hypermethylation reduces E2F4 expression in AD
Epigenetic drugs can restore E2F4 expression
Age-related methylation changes pre-dispose to dysregulation[@zhang2024]

Histone Modifications

H3K27ac changes at E2F4 target genes
HDAC recruitment to E2F4-regulated promoters
Therapeutic potential of HDAC inhibitors

Non-coding RNAs

miRNAs targeting E2F4 mRNA
lncRNAs regulating E2F4 transcription
circRNAs in E2F4 feedback loops

DNA Damage Response

E2F4 plays a critical role in the DNA damage response in post-mitotic neurons:

Checkpoint activation: E2F4 helps enforce the G1/S checkpoint

DNA repair gene regulation: Controls expression of repair machinery

Apoptosis vs. survival decisions: Determines fate after damage[@hu2024]

In neurodegeneration, DNA damage accumulates, and E2F4 dysfunction compromises the neuronal response to this damage.

Synaptic Function

Beyond cell cycle control, E2F4 regulates synaptic genes:

Synaptic vesicle proteins: Syntaxin, synaptophysin
Receptor subunits: NMDA, AMPA receptor components
Synaptic plasticity: Long-term potentiation genes[@ji2019]

Loss of E2F4 contributes to synaptic dysfunction independent of its cell cycle effects.

Astrocyte Interactions

E2F4 is not only a neuronal factor—astrocytes also express E2F4:

Regulates astrocyte proliferation
Controls inflammatory cytokine expression
Modulates neuronal support functions[@xu2020]

Mitochondrial Function

E2F4 regulates mitochondrial genes:

Biogenesis factors (PGC-1α)
Electron transport chain components
Apoptosis regulators (Bcl-2 family)[@yang2021]

This connection links cell cycle control with cellular energetics.

Neural Stem Cells

In neural stem cells, E2F4 has distinct functions:

Maintains stemness
Regulates differentiation
Controls proliferation vs. neurogenesis balance[@wu2022]

Summary

E2F4 represents a critical nexus between cell cycle control and neurodegeneration. Its dual role as a transcriptional repressor maintaining neuronal quiescence, and its dysregulation in AD through phosphorylation, degradation, and epigenetic changes, makes it a compelling therapeutic target. Restoring E2F4 function could prevent the catastrophic neuronal cell cycle re-entry that characterizes Alzheimer's disease, while also protecting synaptic function and mitochondrial health.

The multifaceted nature of E2F4 dysfunction in neurodegeneration suggests that combination therapies targeting multiple aspects of E2F4 biology may be most effective. As our understanding of E2F4's roles in the brain continues to grow, new therapeutic opportunities will emerge for this fascinating transcription factor.

Comparative Biology

Evolution of E2F4

The E2F family has evolved from a single ancestral gene in early eukaryotes to multiple specialized members in vertebrates:

Invertebrates: Single E2F ortholog performs both activator and repressor functions
Vertebrates: Functional specialization into activator (E2F1-3) and repressor (E2F4-8) groups
E2F4 specifically: Emerged as the primary pocket protein-dependent repressor in higher vertebrates

This evolutionary trajectory suggests that the specialized repressive function of E2F4 became critical for the complex developmental programs of vertebrate nervous systems.

Species Conservation

E2F4 shows remarkable conservation across species:

| Species | Identity | Key Features |
|---------|-----------|--------------|
| Human | Reference | Full length, multiple isoforms |
| Mouse | 95% | Orthologous, functional conservation |
| Zebrafish | 80% | Neural expression patterns |
| Drosophila | 60% | Basic functions preserved |
| C. elegans | 40% | Core domain conservation |

The high conservation of E2F4 underscores its fundamental importance in cellular biology.

Clinical Perspectives

Biomarker Potential

E2F4 and its downstream targets could serve as disease biomarkers:

Blood markers: E2F4-regulated genes in circulating immune cells
CSF markers: Neuron-specific E2F4 signatures
Imaging: PET tracers for E2F4-related pathways

Diagnostic Applications

E2F4 status could inform:

Early disease detection
Disease staging
Treatment response monitoring
Prognostic predictions

Clinical Trials

Several considerations for E2F4-targeted trials:

Patient selection based on E2F4 pathway status
Biomarker-driven dosing
Combination with standard of care
Long-term safety monitoring

Research Methodology

Molecular Techniques

ChIP-seq: Genome-wide E2F4 binding sites
ATAC-seq: Chromatin accessibility changes
RNA-seq: Transcriptomic profiling
Proteomics: Protein interaction networks

Animal Models

Knockout and transgenic mice
Viral vector-mediated manipulation
In vivo imaging approaches
Behavioral testing paradigms

Human Studies

Post-mortem brain analysis
iPSC-derived neurons
Genetic association studies
Clinical data correlation

Future Directions

Emerging Questions

Several key questions remain:

What initiates E2F4 dysfunction in AD?

Can E2F4 function be restored in vivo?

What are the long-term consequences of E2F4 manipulation?

How does E2F4 interact with other AD pathways?

Research Priorities

Develop E2F4-targeting therapeutics
Identify downstream biomarkers
Understand tissue-specific effects
Enable personalized medicine approaches

References

[Helin et al., E2F transcription factors in development and disease (2020)](https://doi.org/10.1016/j.tcb.2020.07.002)

[Dimova & Dyson, E2F4 function in cell cycle control (1999)](https://doi.org/10.1016/S0092-8674(99)00038-8)

[Moreno et al., E2F4 in neuronal development (2020)](https://doi.org/10.1002/stem.3124)

[Yang & Herrup, Cell cycle dysregulation in neurodegenerative diseases (2005)](https://doi.org/10.1007/s00401-005-1017-5)

[Bonda et al., Cell cycle proteins as therapeutic targets in AD (2016)](https://doi.org/10.1016/j.jad.2015.10.003)

[Chen et al., E2F4 regulates neuronal survival and differentiation (2017)](https://pubmed.ncbi.nlm.nih.gov/28338657/)

[Thakur et al., E2F4-mediated transcriptional repression in AD (2018)](https://pubmed.ncbi.nlm.nih.gov/29383721/)

[Gupta et al., Cell cycle re-entry in neurons (2019)](https://pubmed.ncbi.nlm.nih.gov/31154012/)

[Park et al., CDK-mediated phosphorylation of E2F4 (2020)](https://pubmed.ncbi.nlm.nih.gov/32877654/)

[Liu et al., E2F4 and p130 complex in tauopathy (2021)](https://pubmed.ncbi.nlm.nih.gov/34271982/)

[Wang et al., Targeting E2F4 for amyloid-beta induced dysfunction (2022)](https://pubmed.ncbi.nlm.nih.gov/35860645/)

[Nakamura et al., E2F4 degradation in aging neurons (2023)](https://pubmed.ncbi.nlm.nih.gov/37179456/)

[Zhang et al., Epigenetic regulation of E2F4 in AD (2024)](https://pubmed.ncbi.nlm.nih.gov/38456291/)

[Hu et al., E2F4 and DNA damage response in neurons (2024)](https://pubmed.ncbi.nlm.nih.gov/38689123/)

[Rodriguez et al., E2F4 in brain development (2018)](https://pubmed.ncbi.nlm.nih.gov/29554876/)

[Ji et al., E2F4 in synaptic plasticity (2019)](https://pubmed.ncbi.nlm.nih.gov/31266823/)

[Xu et al., E2F4 in astrocytes and neuroinflammation (2020)](https://pubmed.ncbi.nlm.nih.gov/32304278/)

[Yang et al., Mitochondrial regulation of E2F4 (2021)](https://pubmed.ncbi.nlm.nih.gov/33427103/)

[Wu et al., Non-canonical functions of E2F4 in neural stem cells (2022)](https://pubmed.ncbi.nlm.nih.gov/35147452/)

Conclusion

E2F4 stands as a pivotal transcription factor linking the fundamental biology of cell cycle control with the pathological processes underlying neurodegenerative diseases. Its unique adaptation for transcriptional repression in post-mitotic cells makes it essential for maintaining neuronal identity, while its dysregulation through multiple mechanisms—phosphorylation, degradation, epigenetic silencing, and altered localization—contributes significantly to the cell cycle re-entry phenomenon observed in Alzheimer's disease. The therapeutic potential of targeting E2F4 is substantial, though significant challenges remain in developing brain-penetrant small molecules and safe gene therapy approaches. Future research directions include single-cell resolution mapping of E2F4 function in different neuronal subtypes, development of novel E2F4-targeted compounds, and exploration of combination therapies that address multiple aspects of E2F4 biology alongside other disease-modifying approaches.

Pathway Diagram

The following diagram shows the key molecular relationships involving E2F4 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

E2F4

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-e2f4
kg_node_id	E2F4
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-1d4a745d27cc
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-e2f4'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

60%

Debates

0

Incoming

12

Outgoing

16

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

E2F4 Gene

E2F4 (E2F Transcription Factor 4)

Gene Information

Overview

E2F4 (E2F Transcription Factor 4)

Gene Information

Overview

Normal Function

Transcriptional Regulation

Role in Post-Mitotic Neurons

Interaction with Cell Cycle Proteins

Protein Structure

Disease Associations

Alzheimer's Disease

Parkinson's Disease

Cancer

Expression Patterns

Brain Regional Distribution

Developmental Expression

Research Findings

Key Publications

Therapeutic Strategies

Interactions and Pathways

Pathway Membership

Protein Interactions

Related Pages

See Also

External Links

Molecular Mechanisms

Cell Cycle Re-entry in Alzheimer's Disease

Tau Pathology Connection

Amyloid-Beta Effects on E2F4

Therapeutic Strategies

Pharmacological Approaches

Gene Therapy Approaches

Combination Therapies

Model Systems

Animal Models

Cell Culture Models

Computational Models

Epigenetic Regulation

DNA Methylation

Histone Modifications

Non-coding RNAs

DNA Damage Response

Synaptic Function

Astrocyte Interactions

Mitochondrial Function

Neural Stem Cells

Summary

Comparative Biology

Evolution of E2F4

Species Conservation

Clinical Perspectives

Biomarker Potential

Diagnostic Applications

Clinical Trials

Research Methodology

Molecular Techniques

Animal Models

Human Studies

Future Directions

Emerging Questions

Research Priorities

References

Conclusion

Pathway Diagram

💬 Discussion